A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.

about

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.

Item

http://www.wikidata.org/entity/Q55339149

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@en

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@nl

type

Item

label

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@en

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@nl

prefLabel

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@en

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@nl

P1476

A CRISPR screen identifies MAP ...... hibition in KRAS mutant NSCLC.

@en

P2093

Benjamin Haley

http://www.w3.org/2001/XMLSchema#string

Christiaan Klijn

http://www.w3.org/2001/XMLSchema#string

Colin Watanabe

http://www.w3.org/2001/XMLSchema#string

Jenna Port

http://www.w3.org/2001/XMLSchema#string

Katherine Leng

http://www.w3.org/2001/XMLSchema#string

Nicholas Dompe

http://www.w3.org/2001/XMLSchema#string

Richard Neve

http://www.w3.org/2001/XMLSchema#string

Trinna Cuellar

http://www.w3.org/2001/XMLSchema#string

P2860

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

P304

e0199264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0199264

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sara A Watson

David Stokoe

Marie Evangelista

P577

2018-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29912950

http://www.w3.org/2001/XMLSchema#string

P921

CRISPR

P932

6005515

http://www.w3.org/2001/XMLSchema#string